Latest Conference Articles

In data presented during the annual ACG meeting, investigators show vedolizumab can be safe and effective for treating pediatric patients with IBD who have failed anti-TNF therapy.

In a new poster presented at the annual ACG meeting in San Antonio, researchers compare morbidity and mortality for ulcerative colitis patients with or without C. diff or CMV infections.

Moira Gunn, PhD, professor of bioentrepreneurship at the University of San Francisco, discusses the biggest hurdles those in healthcare face when looking to create new therapies for rare diseases.

Dawn Rotellini, COO of the National Hemophilia Foundation, discusses how recent policy changes seeking to improve access to and create new therapies for patients with rare diseases.

A review of novel drug approvals in 2018 found more than half of all novel approvals were for rare diseases and that 2018 also saw more novel drug approvals for rare disease than any other year.

A new study shows that bronchoscopy practice, procedure, and tools vary by facility, and in assessment duration.

Dawn Rotellini, chief operating officer of the National Hemophilia Foundation, discusses the important of including patient advocacy groups in annual meetings such as the NORD Summit.

A new analysis of an open-label extension study of the phase 3 PREVENT study is providing further evidence of the safety and efficacy of the treatment of the neuromyelitis optica spectrum disorder.

A new study presented at NORD Summit 2019 found rare disease is underrepresented in published literature and, more often than not, articles are not available in open-access journals.

Dawn Rotellini, chief operating officer of the National Hemophilia Foundation, discusses the impact recent advances in technology and changes in policy focusing on rare diseases have impacted the disease state of hemophilia.

Lucas Kempf, MD, associate director of the FDA's Rare Diseases Program, discusses the impact of recent policy changes that center around increasing access to and creating new therapies for rare disease.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

How the LAMA therapy manages one of the integral facets of COPD care.

While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.

How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?

How the aclidinium bromide trial brings novel perspective to COPD care.

Are diagnostics and drugs optimized for pulmonary hypertension?

New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.

What the introduction of aclidinium/formoterol could mean for patients with COPD.

Katherine Talcott, MD, of Cole Eye Institute, discusses results of a 5-year study examining endogenous bacterial endophthalmitis at a tertiary care center from AAO 2019.

Sumayya Ahmad, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discusses results of a study she presented at AAO 2019 that examined the real-world survival rates of penetrating keratoplasty.

Katherine Talcott, MD, of the Cole Eye Institute, discusses the results of a study she co-authored from AAO 2019 that examined visual acuity outcomes after cataract extraction with IOL implantation with diabetic eyes.

Rishi Singh, MD, of the Cole Eye Institute, discusses the results of an analysis of VIEW trial participants he presented at AAO 2019.

Sumayya Ahmad, MD, assistant professor of ophthalmology at Icahn School of Medicine at Mount Sinai, discusses the results of a study she co-authored examining demographic associations with varying forms of astigmatism

Michael Stewart, MD, of Mayo Clinic Jacksonville, discusses the results of 2 phase 2a studies examining the use of AKST4290 in treatment naive and refractory neovascular age-related macular degeneration.

Aleksandra Rachitskaya, MD, of Cole Eye Institute, discusses a presentation she led at AAO 2019 on novel imaging and surgical techniques.

A new study has found that receiving or not receiving topical antibiotics following cataract surgery had no impact on the development of endophthalmitis.

A phase 1b study, which was presented by Charles Wykoff, MD, PhD, at AAO 2019, found the novel anti-VEGF therapy KSI-301 shows promise for treating a slew of retinal diseases.